Brane Discovery commences Phase I trial of BND-11624 for neuropathic and osteoarthritic pain
The study is a double-blind, placebo-controlled, single ascending dose trial which commenced in early November in Switzerland with the approval of the Swiss National Ethics Committee (SwissMedic). At study completion, 24 healthy volunteers will have been treated, to evaluate safety, tolerability and pharmacokinetics of three different dosages of BND-11624. Administration of the first dose has been completed in all volunteers with excellent tolerability.
"This is the first of a series of candidate drugs that Brane Discovery plans to take in to clinical development. We plan to make Brane into a fully fledged CNS company status within a few years, taking advantage of our promising projects in multiple sclerosis, Parkinson's and Alzheimer's Diseases." said Carlo Farina, CEO of Brane.
Brane Discovery plans to perform a second Phase I repeated-dose trial in Q1 2008, and to start the first Phase II study in HIV patients by Q3 2008. A second indication Phase II study (osteoarthritis-induced pain) should follow after successful clinical PoC in HIV patients, by mid 2009.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.